Gain Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Gain Therapeutics has a total shareholder equity of $8.9M and total debt of $494.4K, which brings its debt-to-equity ratio to 5.5%. Its total assets and total liabilities are $14.4M and $5.5M respectively.
Key information
5.5%
Debt to equity ratio
US$494.41k
Debt
| Interest coverage ratio | n/a |
| Cash | US$12.05m |
| Equity | US$8.91m |
| Total liabilities | US$5.46m |
| Total assets | US$14.37m |
Recent financial health updates
Recent updates
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10Financial Position Analysis
Short Term Liabilities: GANX's short term assets ($13.7M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: GANX's short term assets ($13.7M) exceed its long term liabilities ($861.5K).
Debt to Equity History and Analysis
Debt Level: GANX has more cash than its total debt.
Reducing Debt: GANX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GANX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GANX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.7% each year